These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6840980)

  • 1. The combined effect of quipazine and haloperidol on plasma prolactin release.
    Feigenbaum J; Yanai J; Klawans HL; Chatterton R
    Int J Neurosci; 1983; 18(1-2):37-40. PubMed ID: 6840980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative roles of dopaminergic and serotonergic mechanisms in mediating quipazine induced increases in locomotor activity.
    Feigenbaum JJ; Yanai J; Klawans HL
    J Neural Transm; 1983; 57(1-2):27-37. PubMed ID: 6619829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible dopamine agonist properties of quipazine maleate.
    Feigenbaum JJ; Yanai J; Klawans HL
    Int J Neurosci; 1983; 18(3-4):205-10. PubMed ID: 6222999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic activity of quipazine.
    Schechter MD; Concannon JT
    Pharmacol Biochem Behav; 1982 Sep; 17(3):393-7. PubMed ID: 7146043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of clonidine, quipazine, and LY 53857 on the prolactin-suppressant action of bromocriptine in rats.
    Lipham LB; Booth NH; Jernigan AD; Robbins JD; Hatch RC
    Am J Vet Res; 1986 May; 47(5):1089-91. PubMed ID: 3717731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the serotonin agonist, quipazine, on luteinizing hormone and prolactin release: evidence for serotonin-catecholamine interactions.
    Lynch CO; Johnson MD; Crowley WR
    Life Sci; 1984 Oct; 35(14):1481-7. PubMed ID: 6148678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced head-twitch response to quipazine of rats previously treated with methiothepin: possible involvement of dopaminergic system.
    Dall'Olio R; Vaccheri A; Montanaro N
    Pharmacol Biochem Behav; 1985 Jul; 23(1):43-8. PubMed ID: 2994121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a "serotonergic syndrome" in neonatal rat pups?
    Ristine LA; Spear LP
    Pharmacol Biochem Behav; 1985 Feb; 22(2):265-9. PubMed ID: 2858868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of central acting drugs on prolactin release in young and old male rats.
    Forman LJ; Sonntag WE; Miki N; Ramos T; Meites J
    Proc Soc Exp Biol Med; 1981 Jul; 167(3):354-8. PubMed ID: 6454894
    [No Abstract]   [Full Text] [Related]  

  • 10. Prolactin and luteinizing hormone levels of prelaying, laying and postlaying turkey hens following central administration of serotonin and peripheral administration of quipazine maleate.
    Hargis BM; Burke WH
    Gen Comp Endocrinol; 1984 Jul; 55(1):12-9. PubMed ID: 6235145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quipazine exacerbation of a hyperkinetic syndrome: involvement of brain dopamine and serotonin.
    Langlais PJ; Gabay S
    J Neurosci Res; 1977; 3(2):135-41. PubMed ID: 563925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quipazine-metoclopramide inhibition of CB-154-induced prolactin suppression in rats: neurotransmitter-metabolite correlations.
    Lipham LB; Porter JK; Norred WP; Booth NH; Robbins JD
    Proc Soc Exp Biol Med; 1987 Mar; 184(3):250-5. PubMed ID: 2881309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic-induced reduction of quipazine-elicited head-twitches in rats: possible involvement of striatal dopaminergic supersensitivity.
    Dall'Olio R; Vaccheri A; Gandolfi O; Roncada P; Montanaro N
    Pharmacol Biochem Behav; 1988 Dec; 31(4):941-4. PubMed ID: 2908069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of midbrain raphe lesion or 5,7-dihydroxytryptamine treatment on the prolactin-releasing action of quipazine and D-fenfluramine in rats.
    Quattrone A; Schettini G; di Renzo G; Tedeschi G; Preziosi P
    Brain Res; 1979 Sep; 174(1):71-9. PubMed ID: 487124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional differences in the sensitivity of cholinergic neurons to dopaminergic drugs and quipazine in the rat striatum.
    Guyenet P; Euvrard C; Javoy F; Herbert A; Glowinski J
    Brain Res; 1977 Nov; 136(3):487-500. PubMed ID: 922497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of acute and chronic dexamethasone treatment on stimulated prolactin secretion in the rat.
    Passaro EA; Meltzer HY; Gudelsky GA
    Endocr Res; 1987; 13(2):173-82. PubMed ID: 3497800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the role of the central serotoninergic system in the regulation of the secretion of thyrotropin and prolactin: thyrotropin-inhibiting and prolactin-releasing effects of 5-hydroxytryptamine and quipazine in the male rat.
    Krulich L; Vijayan E; Coppings RJ; Giachetti A; McCann SM; Mayfield MA
    Endocrinology; 1979 Jul; 105(1):276-83. PubMed ID: 446410
    [No Abstract]   [Full Text] [Related]  

  • 18. Serotonergic stimulation of prolactin release in the young turkey (Meleagris gallopavo).
    Fehrer SC; Silsby JL; El Halawani ME
    Gen Comp Endocrinol; 1983 Dec; 52(3):400-8. PubMed ID: 6230284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin and dopamine independently regulate pituitary beta-endorphin release in vivo.
    Sapun-Malcolm D; Farah JM; Mueller GP
    Neuroendocrinology; 1986; 42(3):191-6. PubMed ID: 3005900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of pharmacological manipulation of serotonergic and dopaminergic mechanisms on plasma prolactin in ovariectomized, estrogen-treated rats.
    Lawson DM; Gala RR
    Endocrinology; 1978 Mar; 102(3):973-81. PubMed ID: 311279
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.